127 related articles for article (PubMed ID: 33122039)
1. Expression, purification, and characterization of pneumococcal PsaA-PspA fusion protein.
Guo X; Sun Q; Xi H; Zhang Y; Guo M; Zhang C; Zhu S; Gu T; Kong W; Wu Y
Protein Expr Purif; 2021 Feb; 178():105782. PubMed ID: 33122039
[TBL] [Abstract][Full Text] [Related]
2. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
[TBL] [Abstract][Full Text] [Related]
3. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS
Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027
[TBL] [Abstract][Full Text] [Related]
4. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.
Chen X; Li B; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Zhang Y; Wu Y
Med Microbiol Immunol; 2019 Apr; 208(2):215-226. PubMed ID: 30707297
[TBL] [Abstract][Full Text] [Related]
5. A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains.
Yu J; Chen X; Li B; Gu T; Meng X; Kong W; Wu Y
Immunol Res; 2018 Aug; 66(4):528-536. PubMed ID: 30128745
[TBL] [Abstract][Full Text] [Related]
6. PsaA (pneumococcal surface adhesin A) and PspA (pneumococcal surface protein A) DNA vaccines induce humoral and cellular immune responses against Streptococcus pneumoniae.
Miyaji EN; Dias WO; Gamberini M; Gebara VC; Schenkman RP; Wild J; Riedl P; Reimann J; Schirmbeck R; Leite LC
Vaccine; 2001 Dec; 20(5-6):805-12. PubMed ID: 11738744
[TBL] [Abstract][Full Text] [Related]
7. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
[TBL] [Abstract][Full Text] [Related]
8. Purification and characterization of Streptococcus pneumoniae palmitoylated pneumococcal surface adhesin A expressed in Escherichia coli.
De BK; Sampson JS; Ades EW; Huebner RC; Jue DL; Johnson SE; Espina M; Stinson AR; Briles DE; Carlone GM
Vaccine; 2000 Mar; 18(17):1811-21. PubMed ID: 10699329
[TBL] [Abstract][Full Text] [Related]
9. [Immunoprotective effect of combined pneumococcal endopeptidase O and pneumococcal surface adhesin A vaccines against Streptococcus pneumoniae infection].
Zhang J; Cui YL; Jiang YM
Zhongguo Dang Dai Er Ke Za Zhi; 2017 May; 19(5):583-589. PubMed ID: 28506354
[TBL] [Abstract][Full Text] [Related]
10. Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children.
Zhang Q; Choo S; Finn A
Infect Immun; 2002 Oct; 70(10):5363-9. PubMed ID: 12228260
[TBL] [Abstract][Full Text] [Related]
11. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.
Briles DE; Ades E; Paton JC; Sampson JS; Carlone GM; Huebner RC; Virolainen A; Swiatlo E; Hollingshead SK
Infect Immun; 2000 Feb; 68(2):796-800. PubMed ID: 10639448
[TBL] [Abstract][Full Text] [Related]
12. Identification of the targets of cross-reactive antibodies induced by Streptococcus pneumoniae colonization.
Roche AM; Weiser JN
Infect Immun; 2010 May; 78(5):2231-9. PubMed ID: 20231407
[TBL] [Abstract][Full Text] [Related]
13. Purification and seroreactivity of pneumococcal surface adhesin A (PsaA).
Tharpe JA; Russell H
Clin Diagn Lab Immunol; 1996 Mar; 3(2):227-9. PubMed ID: 8991641
[TBL] [Abstract][Full Text] [Related]
14. Enhanced immunogenicity of pneumococcal surface adhesin A by genetic fusion to cytokines and evaluation of protective immunity in mice.
Gor DO; Ding X; Li Q; Schreiber JR; Dubinsky M; Greenspan NS
Infect Immun; 2002 Oct; 70(10):5589-95. PubMed ID: 12228286
[TBL] [Abstract][Full Text] [Related]
15. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Immunogenicity and Protection of Two Pneumococcal Protein Vaccines Based on PsaA and PspA.
Yu J; Li B; Chen X; Lu J; Wang D; Gu T; Kong W; Wu Y
Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29610257
[No Abstract] [Full Text] [Related]
17. Natural materno-fetal transfer of antibodies to PspA and to PsaA.
Baril L; Briles DE; Crozier P; King JD; Hollingshead SK; Murphy TF; McCormick JB
Clin Exp Immunol; 2004 Mar; 135(3):474-7. PubMed ID: 15008981
[TBL] [Abstract][Full Text] [Related]
18. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae.
Ogunniyi AD; Folland RL; Briles DE; Hollingshead SK; Paton JC
Infect Immun; 2000 May; 68(5):3028-33. PubMed ID: 10769009
[TBL] [Abstract][Full Text] [Related]
19. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae.
Xu JH; Dai WJ; Chen B; Fan XY
Scand J Immunol; 2015 Mar; 81(3):177-85. PubMed ID: 25565478
[TBL] [Abstract][Full Text] [Related]
20. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
Lin H; Peng Y; Lin Z; Zhang S; Guo Y
Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
